OverviewSuggest Edit

AIkido Pharma (formerly known as Spherix) is a biotechnology company engaged in the development of small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

HQBethesda, US

Latest Updates

Employees (est.) (Dec 2019)3(-50%)
Revenue (FY, 2019)$9 K(-67%)
Share Price (Aug 2020)$1.2
Cybersecurity ratingAMore

Key People/Management at AIkido Pharma

Anthony Hayes

Anthony Hayes

Chief Executive Officer, President, Director
Darrell Dotson

Darrell Dotson

VP & General Counsel
Show more

AIkido Pharma Office Locations

AIkido Pharma has offices in Bethesda and New York
Bethesda, US (HQ)
Westmoreland Building, 6430 Rockledge Dr
New York, US
1 Rockefeller Plaza, 10th Floor
Show all (2)

AIkido Pharma Financials and Metrics

AIkido Pharma Revenue

AIkido Pharma's revenue was reported to be $9 k in FY, 2019

Net income (Q2, 2020)


EBIT (Q2, 2020)


Market capitalization (7-Aug-2020)


Closing stock price (7-Aug-2020)


Cash (30-Jun-2020)

AIkido Pharma's current market capitalization is $40.5 m.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Revenue growth, %


Cost of goods sold


Gross profit

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020



Cost of goods sold


Gross profit


Gross profit Margin, %

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Accounts Receivable


Prepaid Expenses


Current Assets

USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

AIkido Pharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Hoth TherapeuticsJune 20, 2017

AIkido Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

AIkido Pharma Online and Social Media Presence

Embed Graph

AIkido Pharma News and Updates

COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights

EXTON, Pa., March 24, 2020 /PRNewswire/ -- Spherix Global Insights is an independent market intelligence firm that focuses on trend-watching in key specialty markets including autoimmune, renal, and CNS indications. On March 10th, in the early days of the COVID-19 outbreak, Spherix...

Spherix Announces $5.75 Million Registered Direct Offering Priced At-the-Market

NEW YORK, March 9, 2020 /PRNewswire/ -- Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, today announced that it has entered into definitive agreements with several institutional and accredited...

Spherix stock soars after option executed for technology in patent for methods to treat coronavirus infection

Shares of Spherix Inc. soared 21% in active morning trading Friday, after the biotechnology company said it executed an exclusive option agreement with the University of Maryland, Baltimore for the technology in the patent for "Methods of Treating Coronavirus Infection." Trading volume swelled to 2…

Spherix Announces Pricing of $7.5 Million Public Offering

NEW YORK, March 3, 2020 /PRNewswire/ -- Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, today announced that it has priced a public offering of an aggregate of 7,142,858 shares of common stock (or...

Spherix Announces a Special Dividend Distribution

NEW YORK, Feb. 23, 2020 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that on February 21, 2020, a special committee of the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 70,000 shares of Hoth Therapeutics,...

Spherix Highlights ValuEngine Upgrade to 'Buy' Rating

NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that its stock has been upgraded to a "buy" rating from a "hold" rating in a research note issued to investors by ValuEngine Inc. (www.valuengine.com). ValuEngine uses proprietary models to...
Show more

AIkido Pharma Frequently Asked Questions

  • When was AIkido Pharma founded?

    AIkido Pharma was founded in 1967.

  • Who are AIkido Pharma key executives?

    AIkido Pharma's key executives are Anthony Hayes and Darrell Dotson.

  • How many employees does AIkido Pharma have?

    AIkido Pharma has 3 employees.

  • What is AIkido Pharma revenue?

    Latest AIkido Pharma annual revenue is $9 k.

  • What is AIkido Pharma revenue per employee?

    Latest AIkido Pharma revenue per employee is $3 k.

  • Who are AIkido Pharma competitors?

    Competitors of AIkido Pharma include Immunochina, Feroscan and Syndivia.

  • Where is AIkido Pharma headquarters?

    AIkido Pharma headquarters is located at Westmoreland Building, 6430 Rockledge Dr, Bethesda.

  • Where are AIkido Pharma offices?

    AIkido Pharma has offices in Bethesda and New York.

  • How many offices does AIkido Pharma have?

    AIkido Pharma has 2 offices.